Objective: To find an optimal correction factor that will produce a near-real renal volume calculation using the ellipsoid formula.

Methods: We retrospectively studied 79 multidetector computed tomography (MDCT) examinations for potential renal donor assessment. The renal volumes were calculated using the slice summation method, the ellipsoid formula with π/6 as correction factors as well multiple other correction factors for statistical analysis. A paired Student t test was used for evaluating the volumes calculated with different correction factors and the volumes calculated by the slice summation method.

Results: The ellipsoid formula using correction factor 0.524 underestimates the renal volume by approximately 22.2% with statistical difference compared with the slice summation method (P<.05). There is no statistical difference when using correction factor in the range of 0.664 to 0.686 (P>.05). Further subgroup analysis of gender and laterality was performed and revealed no statistical difference. Using a mean value of 0.674 or 0.67 as correction factor results in renal volumes that are 100% and 99.5%.

Conclusion: To avoid underestimation of the renal volume by the ellipsoid method, acceptable correction factors are in the range of 0.664 to 0.686. We suggest the use of a mean value of 0.674 or 0.67 as correction factor when using the ellipsoid formula.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.urology.2014.03.005DOI Listing

Publication Analysis

Top Keywords

correction factor
20
renal volume
16
ellipsoid formula
16
correction factors
16
volumes calculated
12
slice summation
12
correction
9
factor ellipsoid
8
volume calculation
8
renal volumes
8

Similar Publications

Infertility is increasing globally, affecting one in six adults due to factors like delayed childbearing and lifestyle changes. Despite the recognition of the importance of increasing fertility awareness, levels remain low. This study evaluated the perceptions of 'FActs!', a serious game aimed at improving adolescents' fertility awareness.

View Article and Find Full Text PDF

Efficacy of cartilage-targeted IGF-1 in a mouse model of growth hormone insensitivity.

Front Endocrinol (Lausanne)

January 2025

Section on Growth and Development, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institute of Health, Bethesda, MD, United States.

Recombinant human IGF-1 is used to treat severe primary IGF-1 deficiency, but this treatment requires twice-daily injection, often does not fully correct the growth deficit, and has important off-target effects. We therefore sought to target IGF-1 to growth plate cartilage by generating fusion proteins combining IGF-1 with single-chain human antibody fragments that target matrilin-3, a cartilage matrix protein. We previously showed that this cartilage-targeting IGF-1 fusion protein (CV1574-1) promoted growth plate function in a GH-deficient (lit) mouse model.

View Article and Find Full Text PDF

Purpose: Recurrent malignant ascites is a common and challenging condition in cancer patients, often lacking a standardized treatment protocol. Small-scale studies in the literature have been insufficient to establish a treatment standard. The aim of our study was to investigate the effectiveness and safety of pigtail peritoneal catheter application in the treatment of malignant ascites.

View Article and Find Full Text PDF

Background: Self-efficacy is one of the factors affecting correct performance, especially in emergency and stressful situations. The mental state of people can affect their performance. The present study was conducted with the aim of determining the relationship between self-esteem and happiness with self-efficacy in the clinical practice of midwives working in medical centers and comprehensive health services in Isfahan city.

View Article and Find Full Text PDF

Hypertensive heart disease and hypertrophic cardiomyopathy both lead to left ventricular hypertrophy despite differing in aetiology. Elucidating the correct aetiology of the presenting hypertrophy can be a challenge for clinicians, especially in patients with overlapping risk factors. Furthermore, drugs typically used to combat hypertensive heart disease may be contraindicated for the treatment of hypertrophic cardiomyopathy, making the correct diagnosis imperative.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!